转移性去势抵抗性前列腺癌（mCRPC）

预约门诊

生存率

生存统计数据

转移性去势抵抗性前列腺癌（mCRPC）的中位预期生存期约为三年。这意味着大约一半确诊这种疾病的患者在三年内死亡，而有大约一半的患者存活更长时间。

转移性去势抵抗性前列腺癌不太可能治愈，但可以治疗。得到这一确诊的大多数患者会因这种癌症去世。

根据美国国家癌症研究所的数据，转移性前列腺癌的五年生存率约为 38%。这意味着，每 100 名转移性前列腺癌患者中，预计约有 38 名患者在确诊后五年仍然存活。这一数字既包括癌症对激素治疗敏感的患者，也包括癌症有耐药性的患者。

请记住，被计入癌症生存率的患者均在五年多前确诊。这些患者可能没有接触过最新疗法。请与医护团队讨论您的预后以及可能影响您个人治疗前景的因素。

预后

转移性去势抵抗性前列腺癌患者的预期生存期取决于许多因素。影响预后的因素包括：

  • PSA 水平。 PSA 水平偏高以及 PSA 水平迅速升高会导致预后较差。
  • 癌症扩散部位。 扩散到淋巴结和骨骼的前列腺癌，预后好于扩散到肝脏和肺部等器官的情况。
  • 癌症扩散部位数量。 癌症扩散部位少，预后好于扩散部位多的癌症。
  • 整体健康状况。 如果患者健康状况不佳并伴有其他严重健康状况，则预后较差。
  • 症状。 如果患者需要使用强效止痛药来帮助控制前列腺癌的症状，则预后较差。

要最清晰、最全面地了解您的治疗前景，请咨询医护团队。医护团队了解您的整体健康状况，可以作出更具个性化的预后判断。

申请预约
诊断与治疗医生与科室
April 29, 2026

Living with 转移性去势抵抗性前列腺癌（mCRPC）?

Connect with others like you for support and answers to your questions in the Prostate Cancer support group on Mayo Clinic Connect, a patient community.

Prostate Cancer Discussions

jcf58
Tulsa Pro Experience, Mayo Clinic MN – July 2024

94 Replies Tue, Jul 14, 2026

jeanadair123
Shrinking penis after surgery and radiation

58 Replies Tue, Jul 14, 2026

buffalo1
Can a dry orgasm after prostatectomy still be pleasurable?

55 Replies Sun, Jul 12, 2026

See more discussions
  1. Dmochowski RR, et al., eds. Campbell-Walsh-Wein Urology. 13th ed. Elsevier; 2026. https://www.clinicalkey.com. Accessed Oct. 2, 2025.
  2. Advanced prostate cancer patient guide. Urology Care Foundation. https://www.urologyhealth.org/educational-resources/advanced-prostate-cancer. Accessed Oct. 2, 2025.
  3. Harris WP, et al. Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion. Nature Clinical Practice Urology. 2009; doi:10.1038/ncpuro1296.
  4. Lowrance W, et al. Advanced prostate cancer: AUA/SUO guideline. https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer. Accessed Oct. 2, 2025.
  5. DeVita VT Jr, et al., eds. Cancer of the prostate. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. ProQuest Ebook Central. Wolters Kluwer; 2023. Accessed Oct. 2, 2025.
  6. Harrington LA, et al., eds. Hormones and cancer. In: The Basic Science of Oncology. 6th ed. McGraw Hill; 2021. https://hemonc.mhmedical.com. Accessed Oct. 2, 2025.
  7. Dawson NA, et al. Overview of the treatment of castration-resistant prostate cancer (CRPC). https://www.uptodate.com/contents/search. Accessed Oct. 2, 2025.
  8. Testosterone test. Testing.com. https://www.testing.com/tests/testosterone. Accessed Oct. 10, 2025.
  9. Prostate cancer. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1459. Accessed Oct. 2, 2025.
  10. Fact sheet: Molecular imaging and prostate cancer. Society of Nuclear Medicine & Molecular Imaging. https://snmmi.org/Patients/Patients/Fact-Sheets/Molecular-Imaging-and-Prostate-Cancer.aspx. Accessed Oct. 10, 2025.
  11. Garje R, et al. Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update. Journal of Clinical Oncology. 2025; doi:10.1200/JCO-25-00007.
  12. Targeted therapy to treat cancer. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies. Accessed Oct. 10, 2025.
  13. Abida W, et al. Management of advanced prostate cancer with germline or somatic homologous recombination repair deficiency. https://www.uptodate.com/contents/search. Accessed Oct. 2, 2025.
  14. Gulley J. Immunotherapy for castration-resistant prostate cancer. https://www.uptodate.com/contents/search. Accessed Oct. 2, 2025.
  15. Fact sheet: Radiopharmaceutical therapy and prostate cancer. Society of Nuclear Medicine & Molecular Imaging. https://snmmi.org/Patients/Patients/Fact-Sheets/Radiopharmaceutical-Therapy-and-Prostate-Cancer.aspx. Accessed Oct. 10, 2025.
  16. Stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). RadiologyInfo.org. https://www.radiologyinfo.org/en/info/stereotactic. Accessed Oct. 10, 2025.
  17. Goldman L, et al., eds. Prostate cancer. In: Goldman-Cecil Medicine. 27th ed. Elsevier; 2024. https://www.clinicalkey.com. Accessed Oct. 10, 2025.
  18. Cancer stat facts: Prostate cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/prost.html. Accessed Oct. 10, 2025.
  19. Choline C 11 injection (approval letter). New Drug Application 203155. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203155. Accessed April 4, 2025.
  20. Harris KM. Allscripts EPSi. Mayo Clinic. April 23, 2024.
  21. Become a comprehensive radiopharmaceutical therapy center of excellence. Society of Nuclear Medicine & Molecular Imaging. https://snmmi.org/Web/Clinical-Practice/Radiopharmaceutical-Therapy-Centers-of-Excellence/Become-a-Comprehensive-Radiopharmaceutical-Therapy-Center-of-Excellence.aspx. Accessed July 29, 2025.
  22. Medical review (expert opinion). Mayo Clinic. Dec. 2, 2025.

相关

相关医疗程序

转移性去势抵抗性前列腺癌（mCRPC）